DE69628298D1 - Immunovektoren zum transport in die zelle und den zellkern - Google Patents

Immunovektoren zum transport in die zelle und den zellkern

Info

Publication number
DE69628298D1
DE69628298D1 DE69628298T DE69628298T DE69628298D1 DE 69628298 D1 DE69628298 D1 DE 69628298D1 DE 69628298 T DE69628298 T DE 69628298T DE 69628298 T DE69628298 T DE 69628298T DE 69628298 D1 DE69628298 D1 DE 69628298D1
Authority
DE
Germany
Prior art keywords
cell
immuno
detectors
transport
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69628298T
Other languages
English (en)
Other versions
DE69628298T2 (de
Inventor
Stratis Avrameas
Gerard Buttin
Therese Ternynck
Faridabano Nato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Pierre et Marie Curie Paris 6
Institut Pasteur de Lille
Original Assignee
Universite Pierre et Marie Curie Paris 6
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Pierre et Marie Curie Paris 6, Institut Pasteur de Lille filed Critical Universite Pierre et Marie Curie Paris 6
Publication of DE69628298D1 publication Critical patent/DE69628298D1/de
Application granted granted Critical
Publication of DE69628298T2 publication Critical patent/DE69628298T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69628298T 1995-07-10 1996-07-10 Immunovektoren zum transport in die zelle und den zellkern Expired - Lifetime DE69628298T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9508316A FR2736642B1 (fr) 1995-07-10 1995-07-10 Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
FR9508316 1995-07-10
PCT/FR1996/001076 WO1997002840A1 (fr) 1995-07-10 1996-07-10 Immunovecteurs utilisables pour le transport intracellulaire et intranucleaire

Publications (2)

Publication Number Publication Date
DE69628298D1 true DE69628298D1 (de) 2003-06-26
DE69628298T2 DE69628298T2 (de) 2004-03-25

Family

ID=9480845

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69628298T Expired - Lifetime DE69628298T2 (de) 1995-07-10 1996-07-10 Immunovektoren zum transport in die zelle und den zellkern

Country Status (11)

Country Link
US (3) US6608034B1 (de)
EP (1) EP0837699B1 (de)
JP (3) JP2000506361A (de)
AT (1) ATE240746T1 (de)
CA (1) CA2224413C (de)
DE (1) DE69628298T2 (de)
DK (1) DK0837699T3 (de)
ES (1) ES2198495T3 (de)
FR (1) FR2736642B1 (de)
PT (1) PT837699E (de)
WO (1) WO1997002840A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2736642B1 (fr) * 1995-07-10 1997-09-12 Pasteur Institut Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
FR2766826B1 (fr) 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
EP1006197A1 (de) * 1998-12-04 2000-06-07 Transgene S.A. Verwendung einer Immunkomplex zur Herstellung eines therapeutischen Mittels zur Verwendung für die Transfektion von einem Polynukleotid in Makropinozyte-Zellen
JP3513068B2 (ja) * 1999-05-12 2004-03-31 浜松ホトニクス株式会社 生細胞の細胞質内標的核酸を検出する方法
FR2805821B1 (fr) 2000-03-01 2004-01-16 Diatos Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires
US8003595B2 (en) 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
US20030032597A1 (en) * 2001-07-31 2003-02-13 Sebestyen Magdolna G. Targeting nucleic acids to a cellular nucleus
US7049286B2 (en) 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
AU2003221118A1 (en) * 2002-03-22 2003-10-08 Bipha Corporation Immunoglobulin/hydrophilic peptide complexes
ES2330115T3 (es) 2003-08-14 2009-12-04 Cellectis Composicion antibacteriana, mas particilarmente contra las bacterias gram-negativas, que comprende un peptido y un agente antibacteriano ventajosamente hidrofobo.
EP1797901A1 (de) 2005-12-16 2007-06-20 Diatos Zelldurchlässige Peptidkonjugate zum Transfer von Nukleinsäuren in Zellen
EP1818395A1 (de) 2006-02-08 2007-08-15 Diatos Zusammensetzungen und Verfahren zur Behandlung der Lysosomen-Speichererkrankungen
AU2012298824B2 (en) 2011-08-23 2017-06-01 President And Fellows Of Harvard College Peptide nanoparticles and uses thereof
CN104244973B (zh) 2012-11-16 2017-10-20 美国联合生物医学公司 针对口蹄疫(fmd)的基于合成肽的紧急疫苗
EP3984554A4 (de) * 2019-06-11 2023-11-08 ONO Pharmaceutical Co., Ltd. Immunsuppressivum

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2334107A1 (fr) * 1975-12-05 1977-07-01 Pasteur Institut Procede de couplage de substances biologiques par des liaisons covalentes
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4599998A (en) * 1984-06-01 1986-07-15 Castillo James D Adjustable polycentric orthopedic appliance hinge
US4812397A (en) * 1987-02-10 1989-03-14 The Regents Of The University Of California MAB-anti-DNA related to nephritis
US5428132A (en) * 1987-10-11 1995-06-27 United States Of America Conjugate and method for integration of foreign DNA into cells
US4952499A (en) * 1988-02-11 1990-08-28 Dana-Farber Cancer Institute Genes and their encoded proteins which regulate gene expression of the interleukin-2 receptor and of human lymphotropic retroviruses
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
ZA914625B (en) * 1990-06-22 1993-02-24 Lilly Co Eli In vivo targeting with bifunctional antibodies
US5733523A (en) * 1990-12-10 1998-03-31 Akzo Nobel N.V. Targeted delivery of a therapeutic entity using complementary oligonucleotides
DE4104186A1 (de) * 1991-02-12 1992-08-13 Genentech Inc Neue, ueber endozytose in hoehere eukaryotische zellen aufnehmbare, nukleinsaeure enthaltende komplexe
AP257A (en) * 1991-04-26 1993-06-03 Surface Active Ltd A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy.
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5922859A (en) 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
EP0656064B1 (de) * 1992-08-17 1997-03-05 Genentech, Inc. Bispezifische immunoadhesine
DE4318402A1 (de) * 1993-06-03 1994-12-08 Boehringer Mannheim Gmbh Verfahren zum Nachweis eines programmierten oder induzierten Zelltods eukaryontischer Zeller
US5681700A (en) * 1994-05-25 1997-10-28 Oklahoma Medical Research Foundation Assay for pathogenicity of anti-DNA antibodies
US5648219A (en) * 1995-06-07 1997-07-15 Zymogenetics, Inc. Immortalized dendritic cells
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
FR2736642B1 (fr) * 1995-07-10 1997-09-12 Pasteur Institut Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
US5616819A (en) * 1995-08-28 1997-04-01 Laroche Industries Inc. Process for preparing fluorinated aliphatic compounds
WO1997032602A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California DELIVERY SYSTEM USING mAb 3E10 AND MUTANTS AND/OR FUNCTIONAL FRAGMENTS THEREOF
US5992859A (en) * 1998-04-27 1999-11-30 Chum Power Machinery Corp. Bit holding system for a power hand tool

Also Published As

Publication number Publication date
PT837699E (pt) 2003-09-30
EP0837699A1 (de) 1998-04-29
JP2010115202A (ja) 2010-05-27
ATE240746T1 (de) 2003-06-15
FR2736642B1 (fr) 1997-09-12
US20110020928A1 (en) 2011-01-27
WO1997002840A1 (fr) 1997-01-30
EP0837699B1 (de) 2003-05-21
JP2008054684A (ja) 2008-03-13
CA2224413A1 (fr) 1997-01-30
FR2736642A1 (fr) 1997-01-17
DE69628298T2 (de) 2004-03-25
DK0837699T3 (da) 2003-09-22
US20040259822A1 (en) 2004-12-23
ES2198495T3 (es) 2004-02-01
US6608034B1 (en) 2003-08-19
CA2224413C (fr) 2009-10-13
JP2000506361A (ja) 2000-05-30
JP4680968B2 (ja) 2011-05-11

Similar Documents

Publication Publication Date Title
DE69628298D1 (de) Immunovektoren zum transport in die zelle und den zellkern
ES530853A0 (es) Un metodo para separar una toxina bacteriana de una muestra biologica
DK609985A (da) Adhesin-antigener, antistoffer mod disse og dna-fragmenter, som indkoder antigenerne
PT799058E (pt) Melhoramentos na funcao endometrica ou com ela relacionados
GB8504104D0 (en) Hcmv monoclonal antibodies
MY106561A (en) Method of making factor-dependent human b cell lines
NZ211989A (en) Monoclonal anticytomegalovirus antibodies and diagnostic system
EP0522169A4 (en) Antihuman stromelysin monoclonal antibody and diagnosis of rheumatoid arthritis by enzyme immunoassay
PT733903E (pt) Processo de dosagem imunologica de cortisol nomeadamente urinario e reagentes utilizados
EP0174874A3 (de) Hybridzellinie die für Trichomonas vaginalis zytolytische, monoklonale Antikörper produziert
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
ATE260115T1 (de) Reduzierte fett-absorption durch anti-lipase antikörper
EP0260599A3 (de) Verfahren und Mittel zum Nachweis von Antikörpern gegen menschliche und tierische Retroviren, insbesondere T-lymphotrope Viren
DE3569161D1 (en) Process for assaying atl virus antibody and reagent therefore
PT83368A (en) Process for propagating microorganisms in vivo by using cell lines which lack human class ii histocompatibility antigens
DK481484D0 (da) Fremgangsmaade til paavisning af virus
WO1999025375A8 (en) DIRECT CYTOTOXIC ACTIVITY BY ANTI-hCG MONOCLONAL ANTIBODIES
ATE343596T1 (de) Humane monoklonale antikörper gegen inselzellantigen ia-2
JPS5531020A (en) Preparation of antiserum for coenzyme
JPS5386014A (en) Quantitative analysis of antigen and antibody
KR950031110A (ko) 인간 혈증 아포지단백질 비-100(b-100)에 대한 신규 단일클론 항체 및 이들의 생산을 위한 재조합 하이브리도마 세포주
ES2061818T3 (es) Anticuerpos monoclonales capaces de reconocer gangliosidos gq1b y gt1a.
BG51002A1 (en) Method for the preparation of monoclonal antibody against 03- salmonellan antigen
RU95114680A (ru) Иммуноагглютинационный диагностикум для скринингового экспресс-анализа онкомаркера в сыворотке и цельной крови
JPS6459068A (en) Method for measuring human thyroxin binding globulin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition